Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 77.81% is 1949% above its 5-year average of 3.80%, near the high end of its 5-year range (-974.00%–100.00%).
17.35% below its 12-month average of 94.14%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
77.81%
GROSS MARGIN AVG TTM
94.14%
GROSS MARGIN AVG 3Y
90.68%
GROSS MARGIN AVG 5Y
3.80%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-17.35%
CURRENT VS 3Y AVG
-14.19%
CURRENT VS 5Y AVG
+1949.13%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.51%
median of 525 covered companies
CURRENT VS SECTOR MEDIAN
+67.30%
vs the sector median at left
C4 Therapeutics, Inc.
Market Cap
$329.49M
Gross Margin
77.81%
TTM Avg
94.14%
3Y Avg
90.68%
5Y Avg
3.80%
Market Cap
$339.93M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
66.67%
Market Cap
$311.25M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
13.20%
Market Cap
$348.63M
Gross Margin
62.61%
TTM Avg
61.15%
3Y Avg
61.24%
5Y Avg
64.05%
Market Cap
$305.38M
Gross Margin
49.14%
TTM Avg
49.09%
3Y Avg
45.86%
5Y Avg
49.48%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | $329.49M | 77.81% | 94.14% | 90.68% | 3.80% |
| Cabaletta Bio, Inc. (CABA)vs › | $334.26M | 0.00% | 0.00% | 0.00% | 0.00% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $339.93M | 0.00% | 50.00% | 75.00% | 66.67% |
| CapsoVision, Inc. (CV)vs › | $318.27M | 50.88% | 53.58% | 54.49% | 54.49% |
| Benitec Biopharma Inc. (BNTC)vs › | $311.25M | 0.00% | 0.00% | 25.00% | 13.20% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $348.63M | 62.61% | 61.15% | 61.24% | 64.05% |
| Embecta Corp. (EMBC)vs › | $348.85M | 59.89% | 63.90% | 65.83% | 67.05% |
| Agenus Inc. (AGEN)vs › | $350.42M | 29.63% | -10.58% | -43.61% | -33.41% |
| Standard BioTools Inc. (LAB)vs › | $305.38M | 49.14% | 49.09% | 45.86% | 49.48% |
| Opus Genetics, Inc. (IRD)vs › | $359.16M | 99.87% | 100.00% | 100.00% | 83.33% |
Gross Margin
77.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 70.72% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 65.89% |
| 2024-09-30 | 86.62% |
| 2024-06-30 | 82.97% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 48.14% |
| 2023-09-30 | 81.98% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | -672.60% |
| 2022-12-31 | -974.00% |
| 2022-09-30 | -339.19% |
| 2022-06-30 | -126.42% |
| 2022-03-31 | -242.34% |
| 2021-12-31 | -32.24% |
| 2021-09-30 | -185.91% |
| 2021-06-30 | -138.07% |
| 2021-03-31 | -176.41% |
| 2020-12-31 | -147.31% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | -139.32% |
| 2019-12-31 | -95.12% |
| 2019-09-30 | -141.39% |
| 2019-06-30 | -144.56% |
| 2019-03-31 | -144.56% |
